Copy number variants in pharmacogenetic genes
Yijing He1, Janelle M Hoskins, Howard L McLeod
1UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Genetic Medicine Building, 120 Mason Farm Rd, Chapel Hill, NC 27599-7360, USA.
Trends in Molecular Medicine
|March 11, 2011
Summary
Copy number variations (CNVs) significantly impact drug efficacy and toxicity, offering a new avenue for personalized medicine beyond single nucleotide polymorphisms (SNPs). Understanding CNVs is crucial for predicting patient response and improving clinical interventions.
Area of Science:
- Pharmacogenomics
- Genetics
- Clinical Pharmacology
Background:
- Drug efficacy and toxicity vary significantly among individuals, a problem not fully explained by single nucleotide polymorphisms (SNPs).
- Copy number variations (CNVs) represent a substantial portion of the human genome and are implicated in various diseases.
- CNVs influence drug metabolism and response, highlighting their importance in pharmacogenetics.
Purpose of the Study:
- To comprehensively evaluate the clinical relevance of CNVs in relation to drug efficacy and toxicity.
- To assess the role of CNVs in disease prevalence across global populations.
- To discuss the potential of CNVs as diagnostic tools for clinical intervention.
Main Methods:
- Review of existing literature on CNVs and their impact on drug response.
- Analysis of data from the Human CNV Project.
- Evaluation of clinical studies investigating CNV associations with drug efficacy, toxicity, and disease prevalence.
Main Results:
- CNVs play a significant role in altering drug metabolizing enzymes and drug response pathways.
- CNVs contribute to variations in drug efficacy and toxicity, impacting patient outcomes.
- The prevalence of specific CNVs varies across different world populations.
Conclusions:
- CNVs are clinically relevant factors influencing drug efficacy, toxicity, and disease susceptibility.
- CNVs offer a promising diagnostic tool for personalized medicine and improved clinical interventions.
- Further research into CNVs is essential for optimizing pharmacogenomic strategies.
More Related Videos
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
02:26Comparing Copy Number Variations and SNPs
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...